Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Artemether/Lumefantrine tablets versus Coartem under fed conditions
PACTR202608584206272Not yet recruiting
- Sponsor
- Fidson Healthcare Plc
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of artemether and lumefantrine in malaria (2 arms), sponsored by Fidson Healthcare Plc. Primary endpoints: Cmax of artemether, AUC0-t of artemether and 3 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
artemetherlumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202608584206272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202608584206272.